Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 7-12

  Witherspoon, Samuel M ^a   Emerson, David L ^a   Kerr, Bradley M ^a   Lloyd, Thomas L ^a   Dalton, William S ^b   Wissel, Paul S ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ELACRIDAR; GLYCOPROTEIN P; RHODAMINE 123; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MONITORING; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ACRIDINES; ANTIGENS, CD56; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; HUMANS; ISOQUINOLINES; P-GLYCOPROTEIN; RHODAMINE 123; TETRAHYDROISOQUINOLINES;

EID: 0030041652     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gottesman, M. M. How cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 53: 747-754, 1993.
2. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., and Salmon, S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy J. Clin. Oncol., 7: 415-424, 1989.
3. Gruber, A., Vitols, S., Norgren, S., Arestrom, I., Peterson, C., Bjorkholm, M., Reizenstein, P., and Luthman, H. Quantitative determination of indr1 gene expression in leukaemic cells from patients with acute leukaemia. Br. J. Cancer. 66: 266-272, 1992.
4. Ludescher, C., Hilbe, W., Eisterer, W., Preuss, E., Huber, C., Gotwald, M., Hoffman, J., and Thaler, J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst., 85: 1751-1758, 1993.
5. Sonneveld, P., Schoester, M., and de Leeuw, K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J. Clin. Oncol., 12: 1584-1591, 1994.
6. Jancis, E. M., Chen, H., Carbone, R., Hochberg, R. B., and Dannies, P. S. Rapid stimulation of rhodamine 123 efflux from multidrug-resistant KB cells by progesterone. Biochem. Pharmacol., 46: 1613-1619, 1993.
7. Pourtier-Manzanedo, A., Didier, A. D., Muller, C. D., and Loor, F. SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drugs. 3: 419-421, 1992.
8. Ludescher, C., Thaler, J., Drach, D., Drach, J., Spitaler, M., Gattringer, C , Huber, H., and Hoffman, J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br. J. Haematol., 82: 161-168, 1992
9. Gruol, D. J., Zee, M. C., Trotter, J., and Bourgeois, S., Reversal of multidrug resistance by RU 486. Cancer Res., 54: 3088-3091, 1994.
10. Chaudhary, P. M., Mechetner, E. B., and Roninson, I. B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood, 80: 2735-2739, 1992.
11. Coon, J S., Wang, Y., Bines, S. D., Markham, P N., Chong, A. S F., and Gebel, H. M. Multidrug resistance activity in human lymphocytes. Hum. Immunol., 32: 134-140, 1991.
12. + T cells: a role in cytotoxic effector function. J. Clin. Immunol., 12: 451-458, 1992.
13. Klimecki, W. T., Futscher, B. W., Grogan, T. M., and Dalton, W. S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 83: 2451-2458, 1994.
14. Drach, D., Zhao, S , Drach, J., Mahadevia, R., Grattringer, C., Huber, H., and Andreef, M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood. 80: 2729-2734, 1992.
15. Chaudhary, P. M., and Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66: 85-94, 1991.
16. Hyafil, F., Vergely, C., Du Vignaud, P., and Grand-Perret, T. In vino and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53: 4595-4602, 1993.
17. Darzynkiewicz, Z., Traganos, F., Staiano-Coico, L., Kapuscinski, J., and Melamed, M. R. Interactions of rhodamine 123 with living cells studied by flow cytometry. Cancer Res., 42: 799-806, 1982.
18. Kessel, D., Beck, W. T., Kukuruga, D., and Schulz, V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res., 51: 4665-4670, 1991.
19. Berman, E., Adams, M., Duigou-Osterndorf, R., Godfrey, L., Clarkson, B., and Andreef, M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood, 77: 818-825, 1991.
20. Van Acker, K. L., Van Hove, L. M., and Boogaerts, M. A. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies. Cytometry, 14: 736-746, 1993.
21. Weaver, J. L., Szabo, G., Jr., Pine, P. S., Gottesman, M. M., and Goldenberg, S. The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int. J. Cancer, 54: 456-461, 1993.
22. Ross, D. D., Wooten, P. J., Sridhara, R., Ordonez, J. V., Lee, E. J., and Schiffer, C A., Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood, 82: 1288-1299, 1993.
23. + acute myeloide leukemia cells. Blood, 82: 3157-3162, 1993.
24. Laredo, J., Huynh, A., Muller, C., Jaffrezou, J., Bailly, J., Cassar, G , Laurent, G., and Demur, C. Effect of the protein kinase C inhibitor staruosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood. 84: 229-237, 1994.
25. Merlin, J., Guerci, A., Marchal, S., Missoum, N., Ramacci, C., Humbert, J., Tsuruo, T., and Guerci, O. Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-Glycoprotein-expressing samples from patients with hematologic malignancies. Blood, 84: 262-269, 1994.
26. Boesch, D., Muller, K., Pourtier-Manzanedo, A., and Loor, F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196: 26-32, 1991.
27. Tong, A. W., Lee, J., Wang, R. M., Dalton, W. S., Tsuruo, T., Fay, J. W., and Stone, M. J. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody. Cancer Res., 49: 4829-4834, 1989.
28. Efferth T., and Volm, M. Antibody-directed therapy of multidrug-resistant tumor cells. Med. Oncol Tumor Pharmacother., 9: 11-19, 1992.